Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels that mediate fast synaptic transmission in the central and peripheral nervous systems, playing key roles in neuromuscular signaling and cognitive processes (StatPearls, 2023). AMPA receptors (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors) are tetrameric ionotropic glutamate receptors that facilitate the majority of fast excitatory neurotransmission in the brain and are essential for synaptic plasticity and memory formation (IUPHAR/BPS, 2024). GABA receptors, primarily the ionotropic GABA-A subtype, are pentameric chloride-selective channels that serve as the primary mediators of inhibitory neurotransmission in the mammalian central nervous system (NCBI, 2022). These three receptor systems collectively maintain the excitatory-inhibitory (E/I) balance required for normal brain function; their dysregulation is central to the pathophysiology of epilepsy, Alzheimer's disease, schizophrenia, and various anxiety disorders (PubMed, 2023). Pharmacological intervention targeting these receptors is diverse, involving agonists like nicotine for nAChRs, non-competitive antagonists like perampanel for AMPA receptors, and positive allosteric modulators like benzodiazepines for GABA-A receptors (PubChem, 2024). Given their widespread expression and critical roles, drugs affecting these targets often require careful dosing to avoid significant side effects such as sedation, respiratory depression, or cognitive impairment.
Agonism, antagonism, and allosteric modulation of ionotropic receptor channels to regulate neuronal excitability and synaptic signaling.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nicotinic acetylcholine receptor, AMPA receptor, and GABA receptor (nAChR, AMPAR, GABAR).